Candida auris continues to challenge infection prevention programs worldwide as cases rise across health care settings and multidrug resistance limits treatment options. In this article, Ayaz Majid, PhD, director of product management at Diasorin, explores why rapid molecular diagnostics are becoming essential tools for identifying colonized patients, supporting isolation protocols, and helping health care facilities prevent outbreaks before they spread.